

**AMENDMENTS TO THE CLAIMS**

Claims 1-2 (cancelled)

Claim 3 (withdrawn): An isolated nucleic acid sequence coding for the immunoglobulin polypeptide or antigen binding fragment thereof of claim 1.

Claim 4 (withdrawn): The nucleic acid of claim 3, wherein the nucleic acid is operably linked to a promoter.

Claim 5 (withdrawn): The nucleic acid of claim 4, wherein the promoter and the nucleic acid are contained in an expression vector.

Claim 6 (withdrawn): The nucleic acid of claim 3, wherein the polypeptide is a monoclonal antibody.

Claim 7 (withdrawn): A cell line transfected, transformed, or infected with a vector containing a nucleic acid of claim 3.

Claim 8 (withdrawn): A method of producing a substantially purified immunoglobulin polypeptide, or an antigen binding fragment thereof, comprising the steps of:

- a. Growing a cell line transformed with the nucleic acid of claim 3 under conditions in which the immunoglobulin polypeptide or antigen binding fragment is expressed; and
- b. Harvesting the expressed immunoglobulin polypeptide or fragment.

Claim 9 (withdrawn): The method of claim 8, wherein the cell line is a hybridoma.

Claim 10 (withdrawn): The method of claim 9, wherein the hybridoma is selected from the group consisting of ATCC No. PTA-4217, ATCC No. PTA-4218, ATCC No. PTA-4244, and ATCC No. PTA-4245.

Claim 11 (withdrawn): The method of claim 8, wherein the immunoglobulin polypeptide is a monoclonal antibody.

Claims 12-14 (cancelled)

Claim 15 (original): An isolated cell line selected from the group consisting of ATCC No. PTA-4217, ATCC No. PTA-4218, ATCC No. PTA-4244, and ATCC No. PTA-4245, or progeny thereof.

Claim 16 (withdrawn): A method for delivering a chemotherapeutic agent to a cancer cell comprising administering a composition comprising an anti- RAAG10 antibody associated with the chemotherapeutic agent, wherein the cancer cell is selected from the group consisting of cancer cells from adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), bone cancer (adamantinoma, aneurismal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, dhordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder and bile duct cancers, gestational trophoblastic disease, germ cell tumors, head and neck cancers, islet cell tumors, Kaposi's Sarcoma, kidney cancer (nephroblastoma, papillary renal cell carcinoma), leukemias, lipoma/benign lipomatous tumors, liposarcoma/malignant lipomatous tumors, liver cancer (hepatoblastoma, hepatocellular carcinoma), lymphomas, lung cancer, medulloblastoma, melanoma, meningiomas, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancers, papillary thyroid carcinomas, parathyroid tumors,

pediatric cancers, peripheral nerve sheath tumors, phaeochromocytoma, pituitary tumors, prostate cancer, posterior uveal melanoma, rare hematologic disorders, renal metastatic cancer, rhabdoid tumor, rhabdomysarcoma, sarcomas, skin cancer, soft-tissue sarcomas, squamous cell cancer, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastatic cancer, and uterine cancers (carcinoma of the cervix, endometrial carcinoma, and leiomyoma).

Claim 17 (withdrawn): The method of claim 16, wherein the chemotherapeutic agent is administered to an individual.

Claim 18 (withdrawn): The method of claim 16, wherein the hybridoma is selected from the group consisting of ATCC No. PTA-4217, ATCC No. PTA-4218, ATCC No. PTA-4244, and ATCC No. PTA-4245 or progeny thereof.

Claim 19 (withdrawn): A method of inhibiting growth of cancer cells in an individual comprising administering to the individual an effective amount of a composition comprising an anti-RAAG10 antibody associated with a chemotherapeutic agent to the individual, wherein the cancer cells are selected from the group consisting of cancer cells from adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), bone cancer (adamantinoma, aneurismal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, dhordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder and bile duct cancers, gestational trophoblastic disease, germ cell tumors, head and neck cancers, islet cell tumors, Kaposi's Sarcoma, kidney cancer (nephroblastoma, papillary renal cell carcinoma), leukemias, lipoma/benign lipomatous tumors, liposarcoma/malignant lipomatous tumors, liver cancer (hepatoblastoma, hepatocellular carcinoma), lymphomas, lung cancer, medulloblastoma, melanoma, meningiomas, multiple endocrine neoplasia, multiple myeloma, myelodysplastic

syndrome, neuroblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancers, papillary thyroid carcinomas, parathyroid tumors, pediatric cancers, peripheral nerve sheath tumors, phaeochromocytoma, pituitary tumors, prostate cancer, posterior unveal melanoma, rare hematologic disorders, renal metastatic cancer, rhabdoid tumor, rhabdomysarcoma, sarcomas, skin cancer, soft-tissue sarcomas, squamous cell cancer, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastatic cancer, and uterine cancers (carcinoma of the cervix, endometrial carcinoma, and leiomyoma).

Claim 20 (withdrawn): The method of claim 19, wherein the chemotherapeutic agent is delivered into the cancer cells.

Claim 21 (withdrawn): The method of claim 19, wherein the anti- RAAG10 antibody is a monoclonal antibody expressed by cell line wherein the hybridoma is selected from the group consisting of ATCC No. PTA-4217, ATCC No. PTA-4218, ATCC No. PTA-4244, and ATCC No. PTA-4245 or progeny thereof.

Claim 22 (withdrawn): A method for detecting the presence or absence of a cancer cell in an individual comprising contacting cells from the individual with an anti- RAAG10 antibody, and detecting a complex of RAAG10 from the cells and the antibody, if any, wherein the cancer cell is selected from the group consisting of cancer cells from adrenal gland tumors, AIDS-associated cancers, alveolar soft part sarcoma, astrocytic tumors, bladder cancer (squamous cell carcinoma and transitional cell carcinoma), bone cancer (adamantinoma, aneurismal bone cysts, osteochondroma, osteosarcoma), brain and spinal cord cancers, metastatic brain tumors, breast cancer, carotid body tumors, cervical cancer, chondrosarcoma, dhordoma, chromophobe renal cell carcinoma, clear cell carcinoma, colon cancer, colorectal cancer, cutaneous benign fibrous histiocytomas, desmoplastic small round cell tumors, ependymomas, Ewing's tumors, extraskeletal myxoid chondrosarcoma, fibrogenesis imperfecta ossium, fibrous dysplasia of the bone, gallbladder and bile duct cancers, gestational trophoblastic disease, germ cell tumors, head and neck cancers, islet cell tumors, Kaposi's Sarcoma, kidney cancer (nephroblastoma, papillary renal cell carcinoma), leukemias, lipoma/benign lipomatous tumors, liposarcoma/malignant lipomatous tumors, liver

cancer (hepatoblastoma, hepatocellular carcinoma), lymphomas, lung cancer, medulloblastoma, melanoma, meningiomas, multiple endocrine neoplasia, multiple myeloma, myelodysplastic syndrome, neuroblastoma, neuroendocrine tumors, ovarian cancer, pancreatic cancers, papillary thyroid carcinomas, parathyroid tumors, pediatric cancers, peripheral nerve sheath tumors, phaeochromocytoma, pituitary tumors, prostate cancer, posterior uveal melanoma, rare hematologic disorders, renal metastatic cancer, rhabdoid tumor, rhabdomyosarcoma, sarcomas, skin cancer, soft-tissue sarcomas, squamous cell cancer, stomach cancer, synovial sarcoma, testicular cancer, thymic carcinoma, thymoma, thyroid metastatic cancer, and uterine cancers (carcinoma of the cervix, endometrial carcinoma, and leiomyoma).

Claim 23 (withdrawn): An agent that blocks at least one of the following interactions between RAAG10 and an RAAG10 binding partner:

- a. the ability to bind to RAAG10 on a cancer cell;
- b. ability to bind to a portion of RAAG10 that is exposed on the surface of a living cell *in vitro* or *in vivo*;
- c. ability to deliver a therapeutic agent or detectable marker to a cancer cell expressing RAAG10; and
- d. ability to deliver a therapeutic agent or detectable marker into a cancer cell expressing A RAAG10;

Claim 24 (withdrawn): A pharmaceutical composition comprising a therapeutically effective dose of an agent according to claim 23, together with a pharmaceutically acceptable carrier.

Claim 25 (currently amended): A purified An isolated antibody capable of binding to an epitope on B7H3L bound by a monoclonal antibody that is expressed by any one of the cell lines

~~of claim 15 a cell line selected from the group consisting of ATCC No. PTA-4217, ATCC No. PTA-4218, ATCC No. PTA-4244, and ATCC No. PTA-4245, or progeny thereof.~~

Claim 26 (cancelled)

Claim 27 (new): The isolated antibody of claim 25, wherein the isolated antibody is a humanized antibody.

Claim 28 (new): The isolated antibody of claim 25, wherein the isolated antibody is a human antibody.

Claim 29 (new): The isolated antibody of claim 25, wherein the isolated antibody is conjugated to a therapeutic agent.

Claim 30 (new): The isolated antibody of claim 25, wherein the isolated antibody is capable of binding to an epitope on B7H3L bound by a monoclonal antibody expressed by the cell line having ATCC No. PTA-4217 or progeny thereof.

Claim 31 (new): The isolated antibody of claim 25, wherein the isolated antibody is capable of binding to an epitope on B7H3L bound by a monoclonal antibody expressed by the cell line having ATCC No. PTA-4218 or progeny thereof.

Claim 32 (new): The isolated antibody of claim 25, wherein the isolated antibody is capable of binding to an epitope on B7H3L bound by a monoclonal antibody expressed by the cell line having ATCC No. PTA-4244 or progeny thereof.

Claim 33 (new): The isolated antibody of claim 25, wherein the isolated antibody is capable of binding to an epitope on B7H3L bound by a monoclonal antibody expressed by the cell line having ATCC No. PTA-4245 or progeny thereof.

Claim 34 (new): An isolated antibody comprising three complementarity determining regions from the heavy chain and three complementarity determining regions from the light chain of

the monoclonal antibody expressed by the cell line having ATCC No. PTA-4217 or progeny thereof.

Claim 35 (new): The isolated antibody of claim 34, wherein the isolated antibody is a humanized antibody.

Claim 36 (new): The isolated antibody of claim 34, wherein the isolated antibody is a chimeric antibody comprising the heavy chain variable region and the light chain variable region of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4217 or progeny thereof, and a heavy chain constant region and a light chain constant region from a human antibody.

Claim 37 (new): An isolated antibody comprising three complementarity determining regions from the heavy chain and three complementarity determining regions from the light chain of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4218 or progeny thereof.

Claim 38 (new): The isolated antibody of claim 37, wherein the isolated antibody is a humanized antibody.

Claim 39 (new): The isolated antibody of claim 37, wherein the isolated antibody is a chimeric antibody comprising the heavy chain variable region and the light chain variable region of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4218 or progeny thereof, and a heavy chain constant region and a light chain constant region from a human antibody.

Claim 40 (new): An isolated antibody comprising three complementarity determining regions from the heavy chain and three complementarity determining regions from the light chain of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4244 or progeny thereof.

Claim 41 (new): The isolated antibody of claim 40, wherein the isolated antibody is a humanized antibody.

Claim 42 (new): The isolated antibody of claim 40, wherein the isolated antibody is a chimeric antibody comprising the heavy chain variable region and the light chain variable region of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4244 or progeny thereof, and a heavy chain constant region and a light chain constant region from a human antibody.

Claim 43 (new): An isolated antibody comprising three complementarity determining regions from the heavy chain and three complementarity determining regions from the light chain of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4245 or progeny thereof.

Claim 44 (new): The isolated antibody of claim 43, wherein the isolated antibody is a humanized antibody.

Claim 45 (new): The isolated antibody of claim 43, wherein the isolated antibody is a chimeric antibody comprising the heavy chain variable region and the light chain variable region of the monoclonal antibody expressed by the cell line having ATCC No. PTA-4245 or progeny thereof, and a heavy chain constant region and a light chain constant region from a human antibody.

Claim 46 (new): An isolated antibody expressed by a cell line having ATCC No. PTA-4217 or progeny thereof.

Claim 47 (new): An isolated antibody expressed by a cell line having ATCC No. PTA-4218 or progeny thereof.

Claim 48 (new): An isolated antibody expressed by a cell line having ATCC No. PTA-4244 or progeny thereof.

Claim 49 (new): An isolated antibody expressed by a cell line having ATCC No. PTA-4245 or progeny thereof.